SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE IMAGE: PETER ADAMS, PH.D., PROFESSOR IN THE TUMOR INITIATION AND MAINTENANCE PROGRAM AT SANFORD BURNHAM PREBYS’ NCI-DESIGNATED CANCER CENTER. CREDIT: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE LA JOLLA, CALIF. – Jan 20, 2020 – Scientists have identified two drugs that are potent against acute myeloid leukemia (AML) when combined,...
Genomic profiles can be used to classify patients by risk of relapse after transplant DANA-FARBER CANCER INSTITUTE For older patients with acute myeloid leukemia (AML), the prospects for success of a stem cell transplant can often be predicted based on the particular set of genetic mutations within the tumor cells, investigators at Dana-Farber Cancer Institute...
A combination of the standard-of-care chemotherapy drug known as azacitidine, with nivolumab, an immune checkpoint inhibitor, demonstrated an encouraging response rate and overall survival in patients with relapsed or refractory acute myeloid leukemia (AML) according to findings from a Phase II study at The University of Texas MD Anderson Cancer Center. Results from the trial,...
Research teams from Massachusetts General Hospital and the Harvard Stem Cell Institute have teamed up to devise a new strategy for treating acute myeloid leukemia (AML). This new strategy is an outgrowth of new findings by these research groups that have identified an enzyme that plays a central role in the onset of AML. During...
